These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38165808)

  • 1. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
    Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.
    Yoo S; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Yoo C; Ryoo BY; Choi J
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):898-907. PubMed ID: 34182151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.
    Baumert LS; Shih AR; Chung RT
    Med; 2024 Feb; 5(2):126-131.e1. PubMed ID: 38340708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy.
    Pan S; Yu Y; Wang S; Tu B; Shen Y; Qiu Q; Liu X; Su N; Zuo Y; Luan J; Zhang JY; Shi M; Meng F; Wang FS
    Front Immunol; 2022; 13():892618. PubMed ID: 35711409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Yang JC; Yu CJ
    Eur J Cancer; 2019 Aug; 117():107-115. PubMed ID: 31279301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy.
    Bal T; Onlen Y
    Arab J Gastroenterol; 2018 Mar; 19(1):33-36. PubMed ID: 29503077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
    Liu S; He Z; Wu W; Jin H; Cui Y
    Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of viral hepatitis B markers among blood donors in the Republic of Guinea].
    Boumbaly S; Balde TAL; Semenov AV; Ostankova YV; Serikova EN; Naidenova EV; Valutite DE; Shchemelev AN; Zueva EB; Esaulenko EV; Totolian AA
    Vopr Virusol; 2022 Mar; 67(1):59-68. PubMed ID: 35293189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
    Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
    Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
    He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
    Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
    Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
    Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
    Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.